Past present and future of radiosensitization in cervical cancer - Takeaways - MDSpire

Past present and future of radiosensitization in cervical cancer

  • By

  • Olivia N. Julian

  • Isabella Velarde

  • Sunil J. Advani

  • Jyoti Mayadev

  • Ramez N. Eskander

  • June 19, 2026

  • 0 min

Share

  • 1

    Cervical cancer causes over 662,000 cases and 348,000 deaths annually, making it a significant global health issue.

  • 2

    Locally advanced cervical cancer (LACC) has a 5-year survival rate of approximately 50% despite being potentially curable.

  • 3

    Cisplatin has been the established radiosensitizer for cervical cancer since the 1990s, with no significant changes in its use.

  • 4

    Antibody drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) show promise in improving outcomes for metastatic cervical cancer.

  • 5

    Combining ADCs with immunotherapy may enhance tumor control in LACC, warranting further investigation.

Original Source(s)

Past present and future of radiosensitization in cervical cancer

  • by Olivia N. Julian, Isabella Velarde, Sunil J. Advani, Jyoti Mayadev, Ramez N. Eskander

  • June 19, 2026

Related Content

Effects of surgery on cancer metastasis: biological mechanisms and perioperative implications

Concordant ETV6::RUNX1-positive acute lymphoblastic leukemia in monozygotic twins: a case report and review of the literature

Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer